A Hemophilia Patient Support Group with over 300 members.
The group admin posted a voting link on the Longtu APP.
"Everyone hurry up and vote! Whether the children's illnesses can be cured depends on our efforts."
"Receive"
"Received +1"
"Received +2"
"Received +3"
Xiaomei's mother is also a family member of a child with Hemophilia. She had heard of the Longtu APP, which is said to be a very popular software recently, but what's the deal with this poll? How does it relate to her child's illness?
She couldn't help but ask curiously, "Group admin, could you please explain what's going on with this poll? How does it relate to the children's illnesses?"
Group admin. "... Are you new here?"
"Yes, I just joined the group today."
"No wonder, that's how it is. You should have heard of Sanqing Pharmaceutical's Gene Drug, right? Longtu APP is also software developed by this pharmaceutical company."
Xiaomei's mother answered timidly, "I've heard of it. I heard that this company is really amazing. They've developed a lot of miraculous drugs. I even registered for this software. It's quite useful."
"You know this, right? They recently held a voting event where every Rare Disease could vote for their own disease. The disease with the most votes will be the one for which they will prioritize developing Gene Drug. Now you know how important this vote is, right?"
Xiaomei's mother was immediately surprised. "Oh, is that so? I have to go vote right away."
She clicked on the link posted by the group admin, and sure enough, it was a voting event officially released by Dragon Map. There were already dozens of Rare Disease options below, such as Albinism, ALS, Osteogenesis Imperfecta, Pulmonary Hypertension, Tuberous Sclerosis, Fabry Disease, and so on.
After searching for a while, I finally found the Hemophilia option, quickly selected it, and then voted.
After the vote was cast, the number of votes for each option was displayed. The number of Hemophilia patients is not small, with tens of thousands nationwide. This option currently has more than 10,000 votes, which, while not far ahead, is certainly in the top ten.
Xiaomei's mother breathed a sigh of relief, feeling a sense of relief, and then carefully looked at the number of votes for each option.
The most voted disease was Type I Diabetes, followed by some common Rare Disease such as ALS Thalassemia. These diseases affect a large number of people, and there are already tens of thousands of votes for these options.
The further down the list of options, the fewer votes there are. For example, Fabre Disease is a rare X chromosome- linked lysosomal storage disorder, with only about 300 patients nationwide. Although the patients are very united and have nearly 300 votes, the overall number is still very small, placing it very low in the rankings.
The diseases ranked last only received a pitiful dozen or so votes, making them truly Rare Disease among Rare Disease.
The last option is 'Other', which patients can select to fill in other Rare Disease not listed above.
Xiaomei's mother took a screenshot of her vote and happily posted it in the group chat.
"Group admin, I've finished voting. Our vote count is pretty high."
The group admin was very pleased. "Not bad, not bad, you've already reached sixth place. Keep it up! Do you know any other Patient Support Group? Anyone with Hemophilia can try to get votes. Let's aim for the top five so that Three Purities's Gene Drug development can consider us sooner."
"At the rate that Sanqing develops a Gene Drug every Three Purities months, we should be able to have Gene Drug available in about a year and a half."
Xiaomei's mother thought the group leader was right and quickly agreed, "Brother, I'll post it on my Moments right away and ask everyone I know to vote for me."
The group admin was silent for a moment before slowly saying, "Xiaomei's mother, didn't you read the voting instructions? Only patients and their families can vote. Even if others open this page, they can't vote."
"Oh, is that so? How does it know if I'm a patient?"
"When you register, you need to verify your identity with your real name and fill in your electronic medical record. Only those who meet the Rare Disease requirement can vote."
"Oh, I see. It seems I can't get votes through Moments. I have a few other Patient Support Group. I'll send them the links and let them vote."
Xiaomei's mother was speechless for a moment, and had no choice but to obediently share the link and continue to solicit votes in other Patient Support Group.
The same scene is also happening in other Rare Disease Patient Support Group, where every patient's family member is working hard to get the most votes and increase the priority of their condition when Three Purities develops Gene Drug.
However, they did not know that Three Purities's research and development of Gene Drug was not entirely based on the number of people.
The large number of patients is only one of the three major factors that led Three Purities to choose to conduct research and development.
The other two factors are sponsorship fees and the decisive factor being the terminal illness index.
Sponsorship fees are easy to understand. Some wealthy people or their families also suffer from Rare Disease. They often spend a lot of money to sponsor pharmaceutical or biotechnology companies to develop new drugs, doing everything they can to save themselves.
The terminal illness index has two aspects: one is whether the disease is fatal, and the other is whether there are available treatments.
Currently, less than 5% of Rare Disease can be effectively intervened or treated. Of the 121 Rare Disease indications, 68 drugs have been approved for marketing in China, 48 of which have been included in medical insurance. Therefore, for these diseases for which there are already drugs available, the priority of developing Gene Drug is obviously not so high.
Like Menkes Syndrome, although there are only 61 cases, the children with the disease usually only live for three or four years. Even with the use of relief drugs such as Copper Histidinate, they cannot live for more than a few years.
Such a disease has an extremely high chance of being terminal, and therefore undoubtedly has a high priority.
In short, all three factors need to be taken into account on Three Purities's list of Rare Disease breakthroughs in order to allocate limited research and development resources and strive to save more patients.
******
Zhang Lei, 42, is a senior executive at a major internet company and the vice president of Tencent. As one of the company's founding members, he has already achieved Fortune freedom.
However, shortly after he turned forty, he discovered that he had been diagnosed with ALS (ALS).
After being diagnosed with this disease, his life took a different turn.
He was a successful business elite in the workplace, but after being diagnosed with ALS, he became a lonely and disappointed terminally ill patient.
Faced with ALS, his defenses had completely collapsed.
ALS Amyotrophic Lateral Sclerosis ALS), also known as Lou Gehrig's disease, is a rare motor neuron disease. The well-known Professor Hawking bravely fought against ALS for many years.
It has been over 100 years since the first case of ALS was discovered, but the cause and treatment have not yet been found in clinical practice. It is a disease that is even more terrible than Cancer. Once diagnosed, it is equivalent to a death sentence.
There are nearly 200,000 ALS patients in China, and tens of thousands more are seeking medical treatment everywhere. Once diagnosed with ALS, the patient's muscles will gradually atrophy, eventually leading to the inability to walk, difficulty breathing and swallowing. About 80% of patients will die within 5 years of diagnosis.
If treatment could be obtained by spending money, Zhang Lei wouldn't have to worry about his life at all.
Unfortunately, no amount of money can help with ALS; there is no cure.
Currently, there is only one drug internationally called "Riluzole," which can extend a patient's lifespan by three months, but it cannot cure ALS.
Doctors often tell patients bluntly that they will generally die within 5 years after diagnosis.
Zhang Lei was instantly filled with despair.
He had only been married and had a child for less than two years, and he was unwilling to give up just like that.
Does having money not guarantee good health?
Even if it meant giving away all his wealth, he was determined to find a way to survive.
So, after much deliberation, he made a crazy decision: to start a company to conquer ALS illness.
Furthermore, he established the "Gradual Healing Mutual Aid Home," providing a platform for ALS patients to communicate and receive treatment.
In just three years, Zhang Lei invested tens of millions of yuan in this platform to build the world's largest single database.
Before Three Purities announced its Gene Drug, this platform already had six drug lines under development. Although they might not be able to be developed successfully in time, they at least gave people with ALS a glimmer of hope and greatly encouraged them, enabling them to face their condition more strongly.
Zhang Lei immediately took notice of Three Purities's Rare Disease Gene Drug research and development. Out of caution, he waited for a while until the second Menkes Gene Therapy, was also launched before he finally made his decision.
Three Purities is indeed capable and has been continuously developing Gene Drug for Rare Disease.
He was immediately thrilled and quickly contacted Three Purities, offering to donate tens of millions of yuan to sponsor the research and development of Gene Drug for ALS.
After some discussion, a crowdfunding campaign for ALS was officially launched on the Longtu APP.
Without hesitation, Zhang Lei immediately donated the first sum of money, amounting to ten million yuan.
He also leveraged his network to conduct extensive publicity and joined forces with an ALS charity to raise funds.
Crowdfunding for ALS is growing rapidly every day at a visible rate.
In just one week, the amount reached tens of millions. Among them, tens of thousands of ALS patients undoubtedly contributed a huge amount. They contributed their strength and money, and almost everyone donated several hundred yuan to raise such a considerable sum.
This amount of money is enough for Three Purities to cover part of its research and development costs.
Soon after, the crowdfunding campaign came to a successful conclusion, raising nearly 60 million yuan. Three Purities also announced that it would establish a special research and development team for ALS and strive to develop Gene Drug as soon as possible.
This is not the first time a scientific research project has been crowdfunded, but it is the first time Gene Drug has been crowdfunded.
The success of the crowdfunding campaign undoubtedly inspired other Rare Disease, who began to follow suit and launch their own crowdfunding campaigns on Dragon Map.
If the crowdfunding campaign is successful, the funds will become a research and development sponsorship fee for Three Purities. If it fails, the funds will be refunded to the user's account.
Therefore, the patients are very reassured, and they just want to expedite the development of Gene Drug for their diseases by Three Purities.
After all, who wouldn't want to be like SMA and Menkes patients, getting a few needles to completely relieve their pain?
However, not all crowdfunding campaigns can be successful immediately. Three Purities undoubtedly has its own standards for choosing the next research and development target. Those that do not meet the standards for the time being can only wait patiently.
With the advancement of crowdfunding and voting activities, the problem of identifying and finding Rare Disease is gradually being solved.
Compared to the management of common and chronic diseases, Rare Disease diseases have greater loyalty to services. Some patients will spontaneously build platforms to help each other, share information, popularize medicines, and share good doctors with other patients.
As the first platform in China that fully serves patients, Dragon Map has not only improved patients' understanding of diseases, enabling them to get diagnosed and treated early, but also united patients to make their voices heard, which has had a certain impact on pharmaceutical companies' drug research and development.
Never before had the patients realized how powerful their unity was.
And the legendary personalized Gene Therapy is actually so close to us.
Just as Three Purities was venturing into the field of Rare Disease, expanding its territory and achieving considerable success.
Global pharmaceutical companies are also eyeing this untapped territory, making early moves and accelerating their expansion.
It's important to understand that the more difficult it is to find medication for Rare Disease, the more opportunities there are for pharmaceutical companies in this field.
From the perspective of market size, compared with the already Red Sea competitive oncology field, Rare Disease represent a huge blue ocean with astonishing market potential.
Major multinational pharmaceutical companies are investing heavily in the research and development of Orphan Drug, such as Novartis, Roche, Bayer, Pfizer, and Takeda.
Compared to other diseases, Orphan Drug development involves relatively high investment, low risk, and high returns, a fact that has been repeatedly proven in overseas markets.
The number of people suffering from many Rare Disease is higher than that of some highly publicized cancers, such as Leukemia and melanoma. Moreover, most Rare Disease are chronic, requiring patients to take medication for life, with an average treatment duration far exceeding that of cancer drugs.
Industry reports indicate that the domestic Rare Disease market is on the verge of taking off, with the market size estimated to exceed US$10 billion within 5-10 years. This would only account for 3%-5% of the global Rare Disease market, or just 10% of the size of the Eagle Country's Orphan Drug market in 2020.
Last month, Pfizer announced a new organizational restructuring in its China region, with Rare Disease being incorporated as one of the six independent business units.
It is understood that Pfizer has launched several Rare Disease in China, mainly covering three areas: Hemophilia, polyneuropathy, and transthyretin amyloid cardiomyopathy.
Recently, AstraZeneca has also made frequent moves in the Rare Disease business. Not only did it announce the formal establishment of the China Rare Disease Business Unit last September, but it also completed a $39 billion acquisition of Rare Disease giant Alexion in July.
Roche Pharmaceuticals, meanwhile, spent $3 billion in August of last year to enter into a multi-target strategic collaboration and licensing agreement with Shape Therapeutics to jointly develop Gene Therapy drugs targeting specific targets in the fields of Parkinson's Disease and rare diseases.
In fact, as early as two years ago, Roche Pharmaceuticals acquired Spark Therapeutics, a pioneer in Gene Therapy, for $4.3 billion. The company has a very rich pipeline, covering hereditary eye diseases, Hemophilia, lysosomal storage diseases, and neurodegenerative Degenerative Diseases.
Three years ago, Takeda Pharmaceuticals spent a huge sum of $65 billion to acquire Shire Pharmaceuticals, a giant in Rare Disease.
According to incomplete statistics, in the past five years, the total value of acquisitions and mergers in the field of Rare Disease has exceeded US$100 billion.
Major pharmaceutical giants are gearing up for a fierce battle in the field of Rare Disease.
Now, a behemoth has stormed into this vibrant and limitless field.
Upon his debut, he carved out a bloody path with unparalleled force, standing atop the peak and looking down upon the world.